Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

BioTech 365

JANUARY 6, 2021

CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global Emerging Insight and Market Forecasts 2020-2030 – ResearchAndMarkets.com CAEL-101: A Fibril-reactive Monoclonal Antibody (mAb) that is Currently in Phase 3 Clinical Development – Global … Continue reading → (..)

Clinical Development 40

Clinical Development Antibody Development Marketing 40

Pharmaceutical Technology

DECEMBER 7, 2022

On AbbVie exercising its licencing option, the company will be responsible for carrying out all clinical development, production and marketing works of the IRF5 inhibitor programme in the future. HotSpot focuses on discovering and developing small-molecule allosteric therapies for cancer and autoimmune ailments.

Development 147

Development Clinical Development Sales Antibody 147

XTalks

JANUARY 22, 2025

seroresponse rate indicating the proportion of participants achieving antibody levels above a predefined protective threshold sustained one year after vaccination. One year post-vaccination, antibody levels remained strong, with geometric mean titers well above the required protective threshold. The findings reveal a remarkable 98.3%

Immune Response 59

Immune Response Vaccine Vaccination Trials 59

pharmaphorum

JUNE 28, 2022

billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don’t respond to current immunotherapies. The biotech has the option to share costs and profits for developing and commercialising the three product candidates in the US.

Antibody 105

Antibody Immune Response Gene Therapy Drugs 105

Pharmaceutical Technology

FEBRUARY 24, 2023

As the Crohn’s disease (CD) therapeutic landscape grows crowded with added therapies, the success of new agents entering the market depends on their ability to show distinction from comparable first-in-class drugs.

Marketing 147

Marketing Development Pharmacy Drugs 147

pharmaphorum

OCTOBER 18, 2022

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7

Antibody 52

Antibody Sales Clinical Trials Clinical Trials 52

Delveinsight

JULY 30, 2021

The primary goal to achieve in the Crohn’s disease therapeutics market, to date, remains the reduction of inflammation that triggers signs and symptoms and improvement of long-term prognosis. However, the market growth is expected to face a threat from an inescapable entry of biosimilars in the approaching years.

Marketing 74

Marketing Drug Delivery Development Clinical Trials 74

Pharmaceutical Technology

MARCH 23, 2023

Pfizer recently announced an agreement to acquire Seagen, a biotech company based in the US with four marketed oncology therapeutic agents and a rich pipeline. Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio.

Licensing 147

Licensing Licensing Sales Trials 147

pharmaphorum

MARCH 15, 2022

It’s an example of a fairly uncommon risk-sharing model, in which an investment group funds a clinical development programme in the hope of a bigger payoff down the line, with rights to the drug staying with the pharma partner. In return, it will get a royalty on sales if the new version gets approved.

Trials 97

Trials Sales Drug Delivery Antibody 97

pharmaphorum

NOVEMBER 18, 2022

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will receive $30 million in an upfront payment , with the potential for up to $2 billion in research, development, regulatory, and sales-based milestones, also.

Antibody 105

Antibody Sales Development Licensing 105

Roots Analysis

OCTOBER 4, 2023

Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. I, recently, worked on a market research report, titled Bispecific Antibodies Market , 2023-2035. In fact, six bispecific antibodies have been approved in 2022. during the period 2023-2035.

Antibody 40

Antibody Genetics Drugs Development 40

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Production 100

Production DNA Drugs Clinical Trials 100

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. A month earlier, Bristol-Myers Squibb paid $200 million upfront for rights to a TIGIT drug developed by Agenus called AGEN1777 in a deal that could be worth up to $1.56

Drugs 98

Drugs Antibody Pharma Companies Development 98

pharmaphorum

MAY 13, 2021

To recap, AZ shelled out $1bn for rights to datopotamab last year, an antibody-drug conjugate (ADC) consisting of an antibody that targets tumours and a lethal payload that kills cancer cells. Latest data from datopotamab showed a response rate of 43% in the 21 heavily pretreated triple-negative breast cancer patients.

Clinical Development 75

Clinical Development Antibody Drugs Trials 75

Delveinsight

NOVEMBER 29, 2020

Recent years started witnessing the emergence of novel treatment approaches that have been keeping the Retinal vein occlusion market in a hyped-up state. Looking at the potential of the pipeline therapies they hold once approved, pharmaceutical companies are charting out a seemingly exciting course in the market.

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

pharmaphorum

NOVEMBER 6, 2020

Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been on the market for several years and has proven to be effective across a wide range of oncology indications. billion in cash. The transaction is expected to close at the end of 2020.

Antibody 85

Antibody Hormones Trials Clinical Trials 85

Delveinsight

AUGUST 17, 2020

The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence.

Marketing 54

Marketing Trials FDA Approval Clinical Development 54

Pharmaceutical Technology

JUNE 6, 2023

XB-002 is a monoclonal antibody conjugated commercialized by Exelixis, with a leading Phase I program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The drug candidate is a second generation antibody drug conjugate.

Antibody 100

Antibody Development Clinical Trials Clinical Trials 100

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. . ” About Ascletis.

Clinical Development 40

Clinical Development Development Clinical Trials Clinical Trials 40

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. Merck is headquartered in Darmstadt, Hesse, Germany.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Worldwide Clinical Trials

JULY 8, 2024

With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare. The goal is to deliver a precise radiation dose to the diseased tissues while minimizing damage to surrounding healthy tissue.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

XTalks

DECEMBER 5, 2024

Among the next generation of obesity drugs, MariTide is a top GLP-1 contender that touts the potential for enhanced efficacy and more convenient, less frequent dosing.

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

pharmaphorum

SEPTEMBER 17, 2020

The UK big pharma hasn’t revealed how much it is paying for rights to the drug candidate, originally developed by US biotech Dogma Therapeutics, which is still in preclinical development. At the moment no oral PCSK9 drugs have started clinical development, and AZ says it intends to start clinical testing of Dogma’s candidate next year.

Drugs 66

Drugs Antibody Sales Branding 66

pharmaphorum

SEPTEMBER 28, 2021

New phase 2 data with their VLA15 vaccine shows that antibody responses from an initial three-dose regimen are initially high, although they start to decline after 18 months in adult subjects.

Vaccine 105

Vaccine Vaccination Bacteria Protein 105

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

MAY 19, 2021

billion in “biobucks” for exclusive rights to a cancer antibody still in the labs of US biotech Agenus, which blocks the TIGIT receptor that is emerging as an immunotherapy target. BMS and Agenus’ antibody codenamed AGEN1777 is bispecific, targeting TIGIT and a second undisclosed target.

Drugs 69

Drugs Antibody Development Clinical Development 69

Pharmaceutical Technology

FEBRUARY 18, 2023

Gevokizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase I program in Metastatic Renal Cell Carcinoma. According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. It was under development for renal cell carcinoma as first line therapy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

XTalks

JUNE 20, 2023

Columvi is a bispecific antibody designed to bind to CD3 on the surface of T cells and CD20 on the surface of B cells in a novel 1:2 structural format where one region of the antibody binds to CD3 and two to CD20. As part of the accelerated approval, Roche will have to conduct confirmatory trials for Columvi.

Antibody 98

Antibody Trials Drugs FDA Approval 98

XTalks

DECEMBER 5, 2024

Among the next generation of obesity drugs, MariTide is a top GLP-1 contender that touts the potential for enhanced efficacy and more convenient, less frequent dosing.

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

Roots Analysis

FEBRUARY 27, 2024

The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

pharmaphorum

NOVEMBER 16, 2021

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. The post Merck’s oral PCSK9 drug matches injectables in early trials appeared first on.

Trials 98

Trials Drugs Sales Clinical Trials 98

pharmaphorum

FEBRUARY 22, 2022

There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch biotech – TargED Biopharmaceuticals – is hoping to disrupt the market with a new and improved therapy.

Drugs 59

Drugs Protein Clinical Development Antibody 59

pharmaphorum

MARCH 3, 2022

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position to bring a shot to market that will protect infants from the life-threatening infection. AZ, Sanofi antibody aces phase 3 trial.

Vaccine 52

Vaccine Vaccination Antibody Trials 52

XTalks

DECEMBER 10, 2021

Zavegepant is an antibody drug that prevents binding of the calcitonin gene-related peptide (CGRP) to the CGRP receptor. CGRP receptor antagonists are a new class of antibody drugs used for migraine treatment. The pain relief effects were sustained for up to 48 hours.

FDA Approval 98

FDA Approval Trials Drugs Sales 98

The Pharma Data

AUGUST 10, 2020

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373. The candidate is built upon a stable, prefusion protein and includes Novavax’s Matrix?M M adjuvant.

Vaccine 52

Vaccine Vaccination Licensing Licensing 52